IL1B and atherosclerosis: These clinical findings indicate that the benefits of IL-1β antagonism on atherosclerosis are solely due to the inhibition of inflammation, and are in agreement with previous experimental studies demonstrating that IL-1β deficiency and IL-1 receptor antagonism were successful in decreasing the severity of lesions in murine models of atherosclerosis [49,50].